Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:42:22.855Z.
Calculation as of: 2026-10-06T15:42:22.855Z.
Quote observation: 2026-10-06T15:40:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$24.83M
EV/Sales Ratio
N/A
TTM Avg
8660.16x
3Y Avg
2951.18x
5Y Avg
1830.92x
Market Cap
$24.44M
EV/Sales Ratio
N/A
TTM Avg
390.99x
3Y Avg
224.70x
5Y Avg
223.08x
Market Cap
$27.60M
EV/Sales Ratio
36.46x
TTM Avg
235.31x
3Y Avg
882.90x
5Y Avg
492.34x
Market Cap
$28.62M
EV/Sales Ratio
125.05x
TTM Avg
354.15x
3Y Avg
539.01x
5Y Avg
539.01x
Market Cap
$22.65M
EV/Sales Ratio
0.25x
TTM Avg
0.37x
3Y Avg
0.25x
5Y Avg
0.21x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $26.66M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.83M | N/A | 8660.16x | 2951.18x | 1830.92x |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | 390.99x | 224.70x | 223.08x |
| InspireMD, Inc. (NSPR)vs › | $27.48M | 1.32x | 8.15x | 11.91x | 8.44x |
| Kyntra Bio, Inc. (KYNB)vs › | $24.09M | N/A | 1.44x | 1.04x | 4.23x |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.60M | 36.46x | 235.31x | 882.90x | 492.34x |
| aTyr Pharma, Inc. (ATYR)vs › | $28.62M | 125.05x | 354.15x | 539.01x | 539.01x |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.65M | 0.25x | 0.37x | 0.25x | 0.21x |
| LeonaBio, Inc. (LONA)vs › | $22.32M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.87M | 20.75x | 66.22x | 47.59x | 61.65x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
